Atlas Trials

Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

Clinical trial NCT07637513 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07637513
Sponsor
PrECOG, LLC.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Limited Stage Small-Cell Lung Cancer
Start date
2027-01-01
Primary completion
2037-11-01
Enrollment
430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.